2019

13/11/2019 Guerbet announces a strategic partnership with InterSystems to extend the deployment of Contrast&Care®

Guerbet announces a strategic partnership with InterSystems to extend the deployment of Contrast&Care®, its IT contrast media injection management solution More effective integration of Contrast&Care® into the IT systems of hospitals and medical imaging centersA complete solution for...

[more]


29/10/2019 Guerbet high in the Gaïa Index for the 2nd year running

An improved ranking, illustrative of the Group’s ambitious CSR policy

[more]


24/10/2019 Revenue at 30 September 2019

Solid growth during the 3rd quarter, in line with the 2019 objectives • Revenue of €603.5 million for the first 9 months • Up 3.8% at current exchange rates and 2.2% at constant exchange rates• Annual objectives confirmed Villepinte, 24 October 2019 - Guerbet (FR0000032526 GBT), a global...

[more]


10/10/2019 Guerbet signs an agreement with icometrix for the exclusive distribution of icobrain, an artificial intelligence medical imaging solution for neuro imaging

Villepinte (France) – October 10, 2019 (8:30 CEST) – Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional medical imaging, today announced that it has signed an exclusive agreement with icometrix for the distribution in France, Italy and Brazil of...

[more]


09/10/2019 Guerbet to participate in the 75th annual meeting of the ASRM (American Society for Reproductive Medicine)

Guerbet will participate in the 75th annual meeting of the American Society for Reproductive Medicine (ASRM). This year’s ASRM Scientific Congress & Expo theme is “Celebrating 75 Years of History and Innovation” in keeping with their anniversary and the critical role of ASRM in focusing on the...

[more]


25/09/2019 2019 half-year results

Activity growth  › Reported revenue of €400.6 million, up 2.8%, in line with the annual objectives › Revenue of €396.5 million at constant exchange rates, up 1.8% Results in line with GEAR 2023 › €61.6 million EBITDA, including significant expenditures to prepare for the...

[more]


24/09/2019 Guerbet and IBM Watson Health announce a second co-development project as part of their strategic partnership for leveraging artificial intelligence in medical imaging

This second agreement is aimed at developing and marketing a software solution to help radiologists and oncologists diagnose and monitor prostate cancer

[more]


Displaying results 1 to 7 out of 24
<< First < Previous 1-7 8-14 15-21 22-24 Next > Last >>